TAK

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine o.

The consensus price target hints at a 26.4% upside potential for Takeda Pharmaceutical Co. (TAK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

SBLK, TAK and STBA made it to the Zacks Rank #1 (Strong Buy) income stocks list on August 17, 2026.

TAK, VLO, PFX, SBLK and RELY have been added to the Zacks Rank #1 (Strong Buy) List on August 17, 2026.

Takeda Pharmaceuticals (TAK) remains a hold, with shares near 52-week highs and uncertainty about a major successor to Entyvio. TAK's Q1 showed 10% revenue growth, but bottom-line weakness from higher taxes and lower operating cash flow due to mounting receivables. Orzeyful's FDA approval is promising, but its commercial impact is likely limited compared to Entyvio; pipeline drugs like zasocitinib offer longer-term potential, but how much is as yet uncertain.

Takeda Pharmaceutical Company Limited (TAK) Q1 2027 Earnings Call Transcript

Takeda Pharmaceutical NYSE: TAK said its first-quarter fiscal 2026 results were in line with its full-year outlook as growth from core brands and newer products largely offset expected declines in its mature portfolio.

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first quarter of fiscal year 2026 (April 1, 2026 to June 30, 2026), marking a period of disciplined execution and operational momentum. Takeda leveraged the resilient performance of its core in-line portfolio to support its long-term strategy, advancing commercial launch preparations and driving critical R&D pipeline milestones. With a clear operational trajectory established in the first quarter.

Japanese drugmaker ​Takeda Pharmaceutical's ‌dengue vaccine ​QDENGA ​has been approved ⁠by ​India's drug ​regulator, making it the ​first ​dengue vaccine to ‌be ⁠approved in the ​country, ​the ⁠company's Indian ​unit ​said ⁠on Monday.